Here are four things to know.
1. Buprenophine for opioid use disorder was previously approved to administer in a tablet, dissolving film and implant form. Sublocade provides a new option for patients who may want to reduce the burden of taking a daily tablet.
2. Sublocade is the first monthly injectable buprenophine treatment.
3. The approval comes after an FDA advisory committee voted 18-1 that the injectable drug could benefit addicts.
4. The injection is expected to be available to US patients in the first quarter of 2018.
More articles on supply chain:
FDA: Biotin supplements may interfere with lab tests
Gilead launches hepatitis drug in China at one-fifth the US price
CVS launches ‘real-time benefits’ tool to increase price transparency
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
